NCT03620643: ROS1 Targeting With Crizotinib in Advanced E-cadherin Negative, ER Positive Lobular Breast Cancer or Diffuse Gastric Cancer Study

NCT03620643
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER++
Other Mutations: 
Breast Cancer Tissue: Invasive lobular carcinoma
Recruitment Status: Recruiting
Ph+ase 2
Drug Category: Tyrosine-Kinase Inhibitor, Endocrine (Hormone) Therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Must have diagnosis of ER++ ILC
Exclusions: Known untreated or symptomatic brain metastases requiring steroids
https://ClinicalTrials.gov/show/NCT03620643

Comments are closed.

Up ↑